サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1709454

感染性腸炎治療の世界市場：治療の種類別・病原体の種類別・投与経路別・流通チャネル別・エンドユーザー別・国別・地域別 - 産業分析、市場規模・シェア、将来予測 (2025年～2032年)

Infectious Enteritis Treatment Market, By Treatment Type, By Pathogen Type, By Route of Administration, By Distribution Channel, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

出版日
ページ情報
英文 311 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
感染性腸炎治療の世界市場：治療の種類別・病原体の種類別・投与経路別・流通チャネル別・エンドユーザー別・国別・地域別 - 産業分析、市場規模・シェア、将来予測 (2025年～2032年)
出版日: 2025年03月04日
発行: AnalystView Market Insights
ページ情報: 英文 311 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

感染性腸炎治療の市場規模は2024年に4億9,054万米ドルとなり、2025年から2032年にかけてCAGR 7.20%で拡大

感染性腸炎治療の市場力学

世界の食中毒の流行による治療需要の増加

食中毒の流行増加は、感染性腸炎治療市場の重要な促進要因です。汚染された食品や水は細菌、ウイルス、寄生虫感染の主な原因であり、下痢や胃腸炎などの症状を引き起こします。世界保健機関（WHO）によると、食中毒は毎年数百万人に影響を及ぼしており、抗生物質、経口補水液（ORS）、プロバイオティクスなどの効果的な治療に対する需要が高まっています。急速な都市化、劣悪な衛生環境、安全でない食品の取り扱い方法が、特に発展途上地域における食中毒の急増に寄与しています。さらに、世界の旅行や貿易により、国境を越えた食中毒病原体の拡散が増加しています。抗生物質耐性菌の増加により、高度な治療法や併用療法の研究がさらに推進されています。啓蒙と衛生を促進する公衆衛生キャンペーンが早期診断率を向上させ、市場の成長を後押ししています。ロタウイルス予防接種のようなワクチン接種プログラムに対する政府や保健機関からの資金提供の増加も、ウイルス性腸炎の重症例を減少させています。全体として、食中毒の発生率の増加と関連する健康リスクが、感染性腸炎治療市場の拡大を促進しています。

感染性腸炎治療市場：主な考察

当社のリサーチアナリストが共有した分析によると、世界市場は予測期間（2025-2032年）に約7.20％のCAGRで毎年成長すると推定されます。

治療の種類別では、2024年には薬物療法が最大の市場シェアを示すと予測されました。

病原体の種類別では、2024年に細菌が主要な病原体の種類でした。

投与経路別では、経口投与が2024年の主要投与経路でした。

流通チャネル別では、2024年の流通チャネルは病院薬局がトップでした。

エンドユーザー別では、2024年の主要エンドユーザーは病院でした。

地域別では、北米が2024年の売上高でトップ

感染性腸炎治療市場：セグメンテーション分析

世界の感染性腸炎治療市場は、治療の種類、病原体の種類、投与経路、流通チャネル、エンドユーザー、地域に基づいてセグメント化されます。

市場は治療の種類に基づいて4つのカテゴリーに分けられます：薬物療法、治療薬、ワクチン、支持療法です。治療薬は、細菌、ウイルス、寄生虫感染の管理において重要な役割を果たすことから、感染性腸炎治療市場において最も支配的なセグメントです。抗生物質は細菌性腸炎に広く処方され、抗ウイルス薬と抗寄生虫薬はそれぞれウイルス感染と寄生虫感染に対処します。抗生物質耐性菌の増加により、併用療法や新世代抗生物質の需要がさらに高まっています。経口補水液（ORS）は、腸炎の一般的な合併症である脱水の管理に不可欠です。急性および慢性の両方の症例において、治療薬が入手しやすく有効であることから、主要な治療選択肢となっています。さらに、オンライン薬局や遠隔医療サービスの台頭により、必須医薬品への患者のアクセスも向上しています。

市場は病原体の種類によって3つのカテゴリーに分けられます：細菌、ウイルス、寄生虫です。細菌性腸炎治療市場は、サルモネラ、大腸菌、赤痢菌などの病原体によって引き起こされる食中毒の高い流行によって、最も支配的な市場となっています。細菌性腸炎は世界的に入院の主な原因となっており、抗生物質や支持療法の需要が増加しています。抗生物質耐性株の増加により、高度な治療法や薬剤併用療法の研究がさらに加速しています。汚染された食品や水は、特に開発途上地域では依然として主要なトランスミッション源です。さらに、安全でない食品習慣に関連した集団発生が、意識向上と予防対策を引き続き後押ししています。細菌セグメントの優位性は、迅速な診断の進歩により、迅速な治療介入を可能にすることでさらに裏付けられています。

感染性腸炎治療市場：地域別分析

北米が感染性腸炎治療市場で大きなシェアを占めているが、これは高いヘルスケア支出と高度な医療インフラが原動力となっています。米国は食中毒の有病率が上昇しており、米国疾病予防管理センター（CDC）は年間約4,800万件の食中毒患者を報告しています。衛生・公衆衛生の意識の高まりと、乳幼児へのロタウイルス予防接種のような強力なワクチン接種プログラムが、市場の成長に寄与しています。カナダでも、汚染された食品や水源に起因する腸炎患者が増加しており、迅速診断ツールや効果的な治療法に対する需要が高まっています。研究開発活動は活発で、抗生物質耐性病原体に対処するための新しい抗生物質やプロバイオティクスに焦点が当てられています。さらに、良好な償還政策と公衆衛生意識を支援する政府の取り組みが市場拡大を後押ししています。遠隔医療やオンライン薬局の増加傾向は、この地域全体の治療へのアクセシビリティを向上させています。全体として、北米の強力なヘルスケアシステム、技術の進歩、予防医療への取り組みが感染性腸炎治療市場の成長を促進しています。

米国は北米の感染性腸炎治療市場を独占しており、その原動力は食中毒の高い流行率と強固なヘルスケア・インフラです。米国疾病予防管理センター（CDC）によると、年間約4,800万人が食中毒に罹患しており、抗生物質、経口補水液（ORS）、プロバイオティクスなどの治療に対する強い需要につながっています。同国では、乳幼児へのロタウイルス予防接種を含むワクチン接種プログラムが確立されており、ウイルス性腸炎の重症例減少に役立っています。迅速PCR検査などの高度な診断技術が、早期発見と効果的な治療を支えています。さらに、抗生物質耐性の細菌感染症が増加していることから、新たな治療法や併用薬の研究が推進されています。衛生と安全な食習慣を促進するための政府の取り組みや公衆衛生キャンペーンの増加が、市場の成長をさらに後押ししています。また、遠隔医療やオンライン薬局サービスの拡大により、全国的に治療へのアクセスが向上しています。全体として、米国市場は強力なヘルスケア政策、技術の進歩、感染症に対する意識の高まりによって後押しされています。

感染性腸炎治療市場：競合情勢

感染性腸炎治療市場は競争が激しく、複数の世界製薬企業が医薬品開発、ワクチン、支持療法に注力しています。グラクソ・スミスクライン、サノフィ、メルクなどの主要企業は、特にウイルス性腸炎の予防に重要なロタウイルスのワクチン生産で頭角を現しています。抗生物質分野では、ファイザー、ジョンソン・エンド・ジョンソン、バイエルなどの企業が、サルモネラ菌や大腸菌などの細菌感染症に対処しています。ノバルティスやアッヴィなどの企業は、感染後の腸内環境の回復に重点を置いており、プロバイオティクス療法の研究が増加しています。市場は、細菌性腸炎の治療で懸念が高まっている抗生物質耐性に対抗するための配合剤の開発で激しい競争を目の当たりにしています。パートナーシップ、合併、買収は、各社がポートフォリオを拡大し、販売網を強化することを目的とする一般的な戦略です。さらに、ロシュやギリアド・サイエンシズのような企業が早期発見のための先端技術を統合することで、迅速診断ツールへの投資も増加しています。新興企業は、発展途上地域の需要を満たすため、費用対効果の高い治療法に注力しています。全体として、強力な研究開発パイプライン、技術的進歩、戦略的提携が感染性腸炎治療市場の競争力学を形成しています。

目次

第1章 感染性腸炎治療市場の概要

  • 調査範囲
  • 市場推定期間

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 感染性腸炎治療の主な市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 感染性腸炎治療市場：産業分析

  • PEST分析
  • ポーターのファイブフォース分析
  • 市場成長の見通し：マッピング
  • 規制体制の分析

第5章 感染性腸炎治療市場：高まる地政学的緊張の影響

  • COVID-19パンデミックの影響
  • ロシア・ウクライナ戦争の影響
  • 中東紛争の影響

第6章 感染性腸炎治療の市場情勢

  • 感染性腸炎治療の市場シェア分析 (2024年)
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 感染性腸炎治療市場：治療の種類別

  • 概要
    • セグメント別シェア分析：治療の種類別
    • 投薬療法
    • 治療法
    • ワクチン
    • 支持療法

第8章 感染性腸炎治療市場：病原体の種類別

  • 概要
    • セグメント別シェア分析：病原体の種類別
    • 細菌
    • ウイルス
    • 寄生虫

第9章 感染性腸炎治療市場：投与経路別

  • 概要
    • セグメント別シェア分析：投与経路別
    • 経口
    • 静脈内（IV）
    • 注射

第10章 感染性腸炎治療市場：流通チャネル別

  • 概要
    • セグメント別シェア分析：流通チャネル別
    • 病院薬局
    • 小売薬局
    • オンライン薬局

第11章 感染性腸炎治療市場：エンドユーザー別

  • 概要
    • セグメント別シェア分析：エンドユーザー別
    • 病院
    • クリニック
    • 外来手術センター（ASC）
    • 小売薬局
    • オンライン薬局

第12章 感染性腸炎治療市場：地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • オランダ
    • スウェーデン
    • ロシア
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋の主要メーカー
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • インドネシア
    • タイ
    • フィリピン
    • その他
  • ラテンアメリカ（LATAM）
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第13章 主要ベンダー分析：感染性腸炎治療業界

  • 競合ダッシュボード
    • 競合ベンチマーク
    • 競合ポジショニング
  • 企業プロファイル
    • GlaxoSmithKline plc
    • Sanofi SA
    • Johnson &Johnson
    • Merck &Co., Inc.
    • Pfizer Inc.
    • Bayer AG
    • Novartis AG
    • AbbVie Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • Takeda Pharmaceutical Company Limited
    • AstraZeneca plc
    • Bristol-Myers Squibb Company
    • Boehringer Ingelheim International GmbH
    • Cipla Limited
    • Gilead Sciences, Inc.
    • Sun Pharmaceutical Industries Ltd

第14章 AnalystViewの全方位的分析

目次
Product Code: ANV4902

REPORT HIGHLIGHT

Infectious Enteritis Treatment Market size was valued at US$ 490.54 Million in 2024, expanding at a CAGR of 7.20% from 2025 to 2032.

The Infectious Enteritis Treatment Market focuses on medications, therapies, and interventions for managing infectious enteritis, an inflammation of the intestines caused by pathogens such as bacteria, viruses, or parasites. This condition leads to symptoms like diarrhea, abdominal pain, nausea, and vomiting. Common causes include rotavirus, norovirus, E. coli, and Salmonella. Treatment options vary based on the infection type and severity, including oral rehydration therapy (ORT), antibiotics, antivirals, and probiotics to restore gut health. Hospitals, clinics, and pharmacies are key providers of these treatments. Increased prevalence of foodborne illnesses and water contamination has fueled market demand. Advancements in rapid diagnostic tools support early detection and timely treatment. Government initiatives promoting awareness and vaccination programs, such as rotavirus immunization, are contributing to market growth. Regions with limited sanitation infrastructure experience a higher burden, driving demand for affordable and accessible treatments. Pharmaceutical companies are actively investing in research to develop targeted therapies and combination drugs to combat resistant pathogens. Overall, the market continues to expand, driven by growing healthcare needs and technological advancements in diagnostics and therapeutics.

Infectious Enteritis Treatment Market- Market Dynamics

Rising prevalence of foodborne illnesses increasing treatment demand globally.

Rising prevalence of foodborne illnesses is a significant driver for the infectious enteritis treatment market. Contaminated food and water are major sources of bacterial, viral, and parasitic infections, leading to conditions such as diarrhea and gastroenteritis. According to the World Health Organization (WHO), foodborne diseases affect millions of people annually, increasing the demand for effective treatments like antibiotics, oral rehydration solutions (ORS), and probiotics. Rapid urbanization, poor sanitation, and unsafe food handling practices contribute to the surge in foodborne illnesses, especially in developing regions. Additionally, global travel and trade have increased the spread of foodborne pathogens across borders. The rise in antibiotic-resistant strains of bacteria has further driven research into advanced therapies and combination treatments. Public health campaigns promoting awareness and hygiene have improved early diagnosis rates, boosting market growth. Increased funding from governments and health organizations for vaccination programs, such as rotavirus immunization, is also reducing severe cases of viral enteritis. Overall, the growing incidence of foodborne illnesses and the associated health risks are driving the expansion of the infectious enteritis treatment market.

Infectious Enteritis Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.20% over the forecast period (2025-2032)

Based on Treatment Type segmentation, Medications was predicted to show maximum market share in the year 2024

Based on Pathogen Type segmentation, bacterial was the leading Pathogen Type in 2024

Based on Route of Administration segmentation, Oral was the leading Route of Administration in 2024

Based on Distribution Channel segmentation, Hospital Pharmacies was the leading Distribution Channel in 2024

Based on end-user segmentation, Hospitals was the leading end user in 2024

On the basis of region, North America was the leading revenue generator in 2024

Infectious Enteritis Treatment Market- Segmentation Analysis:

The Global Infectious Enteritis Treatment Market is segmented on the basis of Treatment Type, Pathogen Type, Route of Administration, Distribution Channel, End User, and Region.

The market is divided into four categories based on Treatment Type: Medications, Therapies, Vaccines, Supportive Care. Medications are the most dominant segment in the infectious enteritis treatment market, driven by their crucial role in managing bacterial, viral, and parasitic infections. Antibiotics are widely prescribed for bacterial enteritis, while antivirals and antiparasitic drugs address viral and parasitic infections, respectively. The growing prevalence of antibiotic-resistant bacteria has further boosted demand for combination therapies and new-generation antibiotics. Oral rehydration solutions (ORS) are essential for managing dehydration, a common complication of enteritis. The accessibility and effectiveness of medications in both acute and chronic cases make them a primary treatment option. Additionally, the rise of online pharmacies and telemedicine services has improved patient access to essential medications.

The market is divided into three categories based on Pathogen Type: Bacterial, Viral, Parasitic. The bacterial segment is the most dominant in the infectious enteritis treatment market, driven by the high prevalence of foodborne illnesses caused by pathogens such as Salmonella, E. coli, and Shigella. Bacterial enteritis is a leading cause of hospitalizations globally, increasing demand for antibiotics and supportive therapies. The rise of antibiotic-resistant strains has further accelerated research into advanced treatments and combination drug therapies. Contaminated food and water remain major transmission sources, especially in developing regions. Additionally, outbreaks linked to unsafe food practices continue to drive awareness and preventive measures. The bacterial segment's dominance is further supported by rapid diagnostic advancements, enabling quicker treatment interventions.

Infectious Enteritis Treatment Market- Geographical Insights

North America holds a significant share of the infectious enteritis treatment market, driven by high healthcare expenditure and advanced medical infrastructure. The United States leads the region due to a rising prevalence of foodborne illnesses, with the Centers for Disease Control and Prevention (CDC) reporting approximately 48 million foodborne illness cases annually. Increased awareness of hygiene and sanitation, along with strong vaccination programs, such as rotavirus immunization for infants, contribute to market growth. Canada is also witnessing a rise in enteritis cases, driven by contaminated food and water sources, increasing demand for rapid diagnostic tools and effective treatments. Research and development activities are robust, focusing on new antibiotics and probiotics to address antibiotic-resistant pathogens. Additionally, favorable reimbursement policies and government initiatives supporting public health awareness are boosting market expansion. The growing trend of telemedicine and online pharmacies is improving accessibility to treatments across the region. Overall, North America's strong healthcare system, technological advancements, and preventive care initiatives are driving growth in the infectious enteritis treatment market.

The United States dominates the infectious enteritis treatment market in North America, driven by a high prevalence of foodborne illnesses and robust healthcare infrastructure. According to the Centers for Disease Control and Prevention (CDC), approximately 48 million people suffer from foodborne illnesses annually, contributing to a strong demand for treatments such as antibiotics, oral rehydration solutions (ORS), and probiotics. The country has well-established vaccination programs, including rotavirus immunization for infants, which helps reduce severe cases of viral enteritis. Advanced diagnostic technologies, such as rapid PCR testing, are supporting early detection and effective treatment. Additionally, the growing issue of antibiotic-resistant bacterial infections is driving research into new therapies and combination drugs. Increased government initiatives and public health campaigns to promote hygiene and safe food practices are further supporting market growth. The expansion of telemedicine and online pharmacy services has also improved accessibility to treatments across the country. Overall, the U.S. market is propelled by strong healthcare policies, technological advancements, and increasing awareness about infectious diseases.

Infectious Enteritis Treatment Market- Competitive Landscape:

The infectious enteritis treatment market is highly competitive, with several global pharmaceutical companies focusing on drug development, vaccines, and supportive therapies. Key players like GlaxoSmithKline, Sanofi, and Merck are prominent in vaccine production, particularly for rotavirus, which is crucial in preventing viral enteritis. Companies such as Pfizer, Johnson & Johnson, and Bayer dominate the antibiotic segment, addressing bacterial infections like Salmonella and E. coli. Increasing research into probiotic therapies is driven by companies like Novartis and AbbVie, focusing on restoring gut health post-infection. The market is witnessing intense competition in developing combination drugs to combat antibiotic resistance, a growing concern in bacterial enteritis treatment. Partnerships, mergers, and acquisitions are common strategies as companies aim to expand their portfolios and enhance distribution networks. Additionally, investments in rapid diagnostic tools are increasing, with firms like Roche and Gilead Sciences integrating advanced technologies for early detection. Emerging players are focusing on cost-effective therapies to meet demand in developing regions. Overall, strong R&D pipelines, technological advancements, and strategic collaborations are shaping the competitive dynamics of the infectious enteritis treatment market.

Recent Developments:

In November 2022, GSK plc received FDA approval for a new oral-dosing applicator-only presentation of ROTARIX, its rotavirus vaccine. This advancement simplifies preparation for healthcare providers by removing the need for dose reconstitution, offering a more convenient option and enhancing GSK's business portfolio.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL INFECTIOUS ENTERITIS TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Bayer AG
  • Novartis AG
  • AbbVie Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Takeda Pharmaceutical Company Limited
  • AstraZeneca plc
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim International GmbH
  • Cipla Limited
  • Gilead Sciences, Inc.
  • Sun Pharmaceutical Industries Ltd

GLOBAL INFECTIOUS ENTERITIS TREATMENT MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Medications
  • Therapies
  • Vaccines
  • Supportive Care

GLOBAL INFECTIOUS ENTERITIS TREATMENT MARKET, BY PATHOGEN TYPE- MARKET ANALYSIS, 2019 - 2032

  • Bacterial
  • Viral
  • Parasitic

GLOBAL INFECTIOUS ENTERITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Intravenous (IV)
  • Injectable

GLOBAL INFECTIOUS ENTERITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL INFECTIOUS ENTERITIS TREATMENT MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers (ASCs)
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL INFECTIOUS ENTERITIS TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Infectious Enteritis Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Infectious Enteritis Treatment Market Snippet by Treatment Type
    • 2.1.2. Infectious Enteritis Treatment Market Snippet by Pathogen Type
    • 2.1.3. Infectious Enteritis Treatment Market Snippet by Route of Administration
    • 2.1.4. Infectious Enteritis Treatment Market Snippet by Distribution Channel
    • 2.1.5. Infectious Enteritis Treatment Market Snippet by End User
    • 2.1.6. Infectious Enteritis Treatment Market Snippet by Country
    • 2.1.7. Infectious Enteritis Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Infectious Enteritis Treatment Key Market Trends

  • 3.1. Infectious Enteritis Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Infectious Enteritis Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Infectious Enteritis Treatment Market Opportunities
  • 3.4. Infectious Enteritis Treatment Market Future Trends

4. Infectious Enteritis Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Infectious Enteritis Treatment Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Infectious Enteritis Treatment Market Landscape

  • 6.1. Infectious Enteritis Treatment Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Infectious Enteritis Treatment Market - By Treatment Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Treatment Type, 2024 & 2032 (%)
    • 7.1.2. Medications
    • 7.1.3. Therapies
    • 7.1.4. Vaccines
    • 7.1.5. Supportive Care

8. Infectious Enteritis Treatment Market - By Pathogen Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Pathogen Type, 2024 & 2032 (%)
    • 8.1.2. Bacterial
    • 8.1.3. Viral
    • 8.1.4. Parasitic

9. Infectious Enteritis Treatment Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
    • 9.1.2. Oral
    • 9.1.3. Intravenous (IV)
    • 9.1.4. Injectable

10. Infectious Enteritis Treatment Market - By Distribution Channel

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Pathogen Type, 2024 & 2032 (%)
    • 10.1.2. Hospital Pharmacies
    • 10.1.3. Retail Pharmacies
    • 10.1.4. Online Pharmacies

11. Infectious Enteritis Treatment Market - By End User

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
    • 11.1.2. Hospitals
    • 11.1.3. Clinics
    • 11.1.4. Ambulatory Surgical Centers (ASCs)
    • 11.1.5. Retail Pharmacies
    • 11.1.6. Online Pharmacies

12. Infectious Enteritis Treatment Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Infectious Enteritis Treatment Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Infectious Enteritis Treatment Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.10. UK
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. UK Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.10.4. UK Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.3.10.5. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.10.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.10.7. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.11. France
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.11.4. France Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.3.11.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.11.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.11.7. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.12. Italy
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.12.4. Italy Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.3.12.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.12.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.12.7. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.13. Spain
      • 12.3.13.1. Overview
      • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.3. Spain Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Spain Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.13.7. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.14. The Netherlands
      • 12.3.14.1. Overview
      • 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.3. The Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.14.4. The Netherlands Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.3.14.5. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.14.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Overview
      • 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.15.7. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.16. Russia
      • 12.3.16.1. Overview
      • 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.3. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Russia Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.16.7. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.17. Poland
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Poland Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.18. Rest of Europe
      • 12.3.18.1. Overview
      • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.18.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.18.4. Rest of the Europe Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.3.18.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.18.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Infectious Enteritis Treatment Key Manufacturers in Asia Pacific
    • 12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 12.4.5. APAC Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
    • 12.4.6. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.8. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.9. China
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.9.4. China Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.4.9.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.9.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.9.7. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.10. India
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.10.4. India Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.4.10.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.10.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.10.7. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.14. Indonesia
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Indonesia Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.15. Thailand
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Thailand Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.5. Latin America (LATAM)
    • 12.5.1. Overview
    • 12.5.2. Infectious Enteritis Treatment Key Manufacturers in Latin America
    • 12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 12.5.5. LATAM Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
    • 12.5.6. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.8. LATAM Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Infectious Enteritis Treatment Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Infectious Enteritis Treatment Industry

  • 13.1. Competitive Dashboard
    • 13.1.1. Competitive Benchmarking
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. GlaxoSmithKline plc
    • 13.2.2. Sanofi S.A.
    • 13.2.3. Johnson & Johnson
    • 13.2.4. Merck & Co., Inc.
    • 13.2.5. Pfizer Inc.
    • 13.2.6. Bayer AG
    • 13.2.7. Novartis AG
    • 13.2.8. AbbVie Inc.
    • 13.2.9. Eli Lilly and Company
    • 13.2.10. F. Hoffmann-La Roche Ltd
    • 13.2.11. Takeda Pharmaceutical Company Limited
    • 13.2.12. AstraZeneca plc
    • 13.2.13. Bristol-Myers Squibb Company
    • 13.2.14. Boehringer Ingelheim International GmbH
    • 13.2.15. Cipla Limited
    • 13.2.16. Gilead Sciences, Inc.
    • 13.2.17. Sun Pharmaceutical Industries Ltd

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us